Betaville

Abbvie purchases Cerevel Therapeutics for $8.7 billion

Abbvie has announced the $8.7 billion acquisition of US-listed Cerevel Therapeutics, marking its second multi-billion dollar second acquisition in the space of week.

Now, I have to admit little old Betaville is in a bit of grump about this deal announcement as I had been chasing down this story down over the last 24 hours. Grrrrrr...